ClinicalTrials.gg
RecruitingNCT07154186Updated Sep 5, 2025

Triglycerides Glucose Index on Angiographic Profiling of Non-Diabetic Premature Coronary Artery Disease Patients

An observational study in Triglycerides Glucose Index, Angiographic Profiling and Non-Diabetic, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by Sohag University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
180
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Premature Birth with a site in Egypt — 17 open to participants now, 18 under way, 4 of them phase 3. Premature Birth · Egypt.

Planned enrollment
5th of 16
180 · median 100
Started
2025
with 3 others
Observational
16 of 78
4 open now
Primary completion
2026-02
later than 9 of 17 live
Registered
72nd of 78
by date

Among the 78 studies in Premature Birth with a site in Egypt, this one is the 5th largest by planned enrollment of the 16 observational ones that give a count, is one of 4 that started in 2025, is one of 16 observational ones, reaches primary completion later than 9 of the 17 other live ones, and was the 72nd registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

17 of the 78 studies in Premature Birth with a site in Egypt are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Premature Birth with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to evaluate the impact of the triglyceride-glucose (TyG) index on the angiographic profiling of non-diabetic patients with premature coronary artery disease (CAD).

Read the detailed description

Premature coronary artery disease (CAD), defined as CAD occurring before the age of 55 in men and 65 in women, has emerged as a growing health concern worldwide.

Insulin resistance and associated metabolic alterations are strongly implicated in premature atherosclerosis. Even in non-diabetic individuals, subclinical insulin resistance promotes endothelial dysfunction, oxidative stress, and low-grade inflammation, leading to early vascular damage.

The triglyceride-glucose (TyG) index, calculated using fasting glucose and triglyceride levels, has emerged as a cost-effective surrogate marker for insulin resistance.

03

Conditions studied

  • Triglycerides Glucose Index
  • Angiographic Profiling
  • Non-Diabetic
  • Premature
  • Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This cross-sectional study will be conducted at Sohag University Hospitals, following approval from the institutional ethics committee.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years old.
  • Both sexes.
  • Non-diabetic patients [no history of diabetes, (HbA1C) \< 6.5%, fasting glucose \< 126 mg/dL].
  • Confirmed diagnosis of coronary artery disease (CAD) by coronary angiography.

Exclusion criteria

Exclusion Criteria:

  • Known diabetes mellitus (type 1 or type 2).
  • Previous history of coronary revascularization.
  • Severe hepatic or renal dysfunction [ (ALT)/aspartate aminotransferase (AST) ≥ 5× (ULN), estimated (eGFR)\< 30 mL/min/1.73 m²].
  • Malignant disease, disease, or systemic inflammatory disorders.
  • Current use of triglyceride-lowering medications.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
180 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group L

    Patients with a low triglyceride-glucose (TyG) index tertile.

    Other: Coronary Angiographic Assessment

  • Group H

    Patients with a high triglyceride-glucose (TyG) index tertile.

    Other: Coronary Angiographic Assessment

Interventions

  • OtherCoronary Angiographic Assessment

    Coronary angiographic assessment will be performed for all patients.

06

What researchers measure

Primary outcomes

  1. Incidence of ischemia- driven revascularization

    Incidence of ischemia- driven revascularization will be recorded.

    Time frame: 6 months post-procedure

Secondary outcomes

  1. Association between triglyceride-glucose index and single-vessel disease

    The association between the triglyceride-glucose (TyG) index and single-vessel disease (SVD) will be recorded.

    Time frame: 6 months post-procedure

  2. Association between triglyceride-glucose index and two-vessel disease

    The association between the triglyceride-glucose index (TyG) and two-vessel disease (2VD) will be recorded.

    Time frame: 6 months post-procedure

  3. Association between triglyceride-glucose index and three-vessel disease

    The association between the triglyceride-glucose index (TyG) and three-vessel disease (3VD) will be recorded.

    Time frame: 6 months post-procedure

  4. Correlation of the triglyceride-glucose index with traditional cardiovascular risk factor

    Correlation of the triglyceride-glucose index with traditional cardiovascular risk factor will be recorded.

    Time frame: 6 months post-procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Feb 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 4, 2025
StartActual
Sep 4, 2025
Primary completionEst.
Feb 1, 2026
CompletionEst.
Feb 1, 2026
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07154186
Lead sponsor
Sohag University
Responsible party
Remon Saleh Adly (Lecturer of Cardiovascular, Faculty of Medicine, Sohag University, Sohag, Egypt., Sohag University) — Principal investigator
First posted
Sep 4, 2025
Start date
Sep 4, 2025
Primary completion
Feb 1, 2026 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Sep 5, 2025

Study contacts

Remon S Adly, MD
Contact
remonsaleh@yahoo.com
00201221878986

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion